DOUG MANION M.D., FRCP(C)
CHIEF EXECUTIVE OFFICER
Dr. Manion has 20 years of experience in drug development. He was Senior Vice President, Head of Specialty Development and Head of Japan and China R&D at BMS until October 2016. He held leadership roles at BMS overseeing various therapeutic areas, including virology, immunoscience, neurology, cardiology, metabolic diseases, genetically-defined diseases and fibrosis since joining in 2005. From 2001 to 2005, he was Vice President of Clinical Development and Medical Affairs for HIV/AIDS at GSK. He started his career at DuPont Pharmaceuticals in 1997. He is Board Certified in Internal Medicine and completed his Fellowship in Infectious Diseases in Ottawa, Canada, and a clinical and bench research fellowship at Massachusetts General Hospital and Harvard Medical School. Doug also serves on the Board of Directors of Celleron Therapeutics.
LUCA RASTELLI, PH.D.
CHIEF SCIENTIFIC OFFICER
Dr. Rastelli has more than 20 years of drug discovery and development experience at bio-pharmaceutical companies. He was Vice President for Oncology and Translational Sciences at BioXcel Therapeutics until March 2018. Previously, he has held multiple preclinical and clinical project leadership positions at Curagen, Sopherion, EMD Serono and Boston Strategics. He was also involved in the set up and early development of the approved immuno-oncology agent Bavencio (anti-PDL1) and he discovered the target and led initial development of Glembatumumab vedotin (CR011 anti-GPNMB). His academic training was focused on how developmental biology affects cancerogenesis. For this work, he received the American Brain Tumor Association’s 25th Anniversary Translational grant while at the Department of Neuro-Oncology, MD Anderson Cancer Center. Dr. Rastelli received his Ph.D in developmental biology from the University of Geneva, Switzerland.
DAVID SPIEGEL, M.D., PH.D.
Dr. Spiegel is the Chief Scientific Advisor and co-founder of Kleo Pharmaceuticals. He is a Professor of Chemistry and Pharmacology at Yale University where he heads the Spiegel Research Group. He has co-authored over 50 peer-reviewed publications and is an inventor with over a dozen patents, including those that underlie Kleo's ARM, SyAM and MATE platforms. He has been recognized with various awards and honors, including the NIH Director's New Innovators Award, the Ellison Medical Foundation New Scholar Award in Aging Research, the Bill and Melinda Gates Foundation Grand Challenges Explorations Award, an Alfred P. Sloan Foundation Fellowship, an Arthur C. Cope Early Career Scholars Award, and others. David received a B.A from Harvard University and a M.D./Ph.D. from Yale University.
DAVID SPIEGEL, M.D., PH.D.
Mr. Prieb is a technology entrepreneur with over 20 years of experience in business strategy, development, and operations. Prior to co-founding Kleo Pharmaceuticals, he launched, funded, and grew several digital media ventures including Saaspire, Kellogg Media Group, Qiosk.com and JibJab.com. Early in his career, he was a management consultant with The Boston Consulting Group, where he executed strategy and reengineering projects for large banks and financial institutions in Asia. He received his B.A. from Harvard University Magna Cum Laude and M.B.A. from The Wharton School, University of Pennsylvania.